Guj. Inject(Ker) (524238)

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹15.79 with a market cap of only ₹23 crore, this is a micro-cap pharma, but small size alone never makes a good investment. I first look for an enduring moat, and I don't see it. Sales have fallen 48% and profits have fallen 81%; the latest quarter shows just ₹2 crore of revenue and zero net profit. A business with no earnings cannot support a P/E of 376. That multiple simply tells me the denominator has collapsed, not that the company is expensive or cheap. The P/B of 2.46 is more concerning: I am being asked to pay 2.5 times book value for a company whose book value is only ₹6.43 per share and whose ROE is 2.6%. That is far below what a dull fixed deposit would earn. ROCE of 13.48% looks better, but with no net profit in the latest quarter, I would not rely on it. The Piotroski score of 3 out of 9 reinforces my caution; this is a company with weak fundamentals and poor financial signals. There is no dividend, no promoter-holding data and no debt/equity ratio disclosed, so I cannot even complete the basic governance and balance-sheet check. The stock has crashed from ₹115.50 to ₹15.79, about 86% down, and a falling knife sometimes carries a sharp edge. In Graham's language, price is what you pay and value is what you get. I get no evidence of durable value here. I need to see sales stabilize, profits return, and proof that management can earn adequate returns on capital. Until then, this is not a business I can intelligently value, and in that situation I pass.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer